By Chris Wack
Oragenics Inc. shares were up 29% to 17 cents Thursday after the company said no toxicity signals or adverse events were present in its Good Laboratory Practices toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 Covid-19 intranasal vaccine candidate.
The company said it believes the findings of the final toxicology report, including a full histopathology evaluation, confirm a safety and immunogenicity profile that further supports its plan to submit regulatory filings required to progress to a Phase 1 clinical study.
Oragenics said it expects to provide an update on a regulatory pathway in the first quarter of 2023.
The objectives of the toxicology study were to evaluate the potential toxicity and confirm the immunogenicity of the NT-CoV2-1 Covid-19 vaccine following repeated intranasal administration at the maximal dose anticipated to be used in humans.
The stock closed Wednesday’s session down 19% and is down 62% year-to-date.
Write to Chris Wack at chris.wack@wsj.com
Most bear markets end with stock investors in deep despair.
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.
Visit a quote page and your recently viewed tickers will be displayed here.
